Literature DB >> 15953945

[G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients].

Nelson Wohllk G1, Emiliano Soto C, Maritza Bravo A, Pedro Becker C.   

Abstract

BACKGROUND: Medullary thyroid carcinoma (MTC) may occur either as sporadic or as hereditary. Even though the sporadic form corresponds to the majority of cases, the pathogenesis is still unclear. Several polymorphisms of the ret proto-oncogene, including those located in exon 11, 13, 14 and 15 have been described in the general population and some of them seem to be over-represented in sporadic MTC patients from European countries, especially G691S, L769L and S836S. AIM: To evaluate the allele frequencies of these variants in Chilean patients and controls and to determine if these polymorphisms would be associated with the development of sporadic MTC from a different genetic population base. SUBJECTS AND METHODS: Fifty sporadic MTC patients and 50 normal subjects were tested for G691S, L769L, S836S and S904S polymorphisms. The extracted genomic DNA was initially analyzed by direct sequencing of PCR products in patients. The presence or absence of each polymorphism was also assessed in patients and in control by restriction digestion.
RESULTS: The allele frequencies showed a similar level of the G691S, L769L and S904S variants in both groups. Of interest, we found an under-representation of S836S polymorphism in the sporadic MTC group but this number was not statistically significant (p=0.141).
CONCLUSIONS: We did not find an over representation of the G691S, L769 and S836S. These results argue against the validity of the association of these polymorphisms as contributing factors in the development of sporadic MTC based on a Chilean population and raise questions about the importance of these polymorphisms overall.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953945     DOI: 10.4067/s0034-98872005000400001

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  7 in total

1.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

3.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

4.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

Review 5.  Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms.

Authors:  Lucieli Ceolin; Débora R Siqueira; Mírian Romitti; Carla V Ferreira; Ana Luiza Maia
Journal:  Int J Mol Sci       Date:  2011-12-27       Impact factor: 5.923

6.  Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome.

Authors:  Nikoletta Lendvai; Miklos Tóth; Zsuzsanna Valkusz; Gabriella Bekő; Nikolette Szücs; Eva Csajbók; Péter Igaz; Balázs Kriszt; Balázs Kovács; Károly Rácz; Attila Patócs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

7.  Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.

Authors:  Lucieli Ceolin; Mirian Romitti; Débora Rodrigues Siqueira; Carla Vaz Ferreira; Jessica Oliboni Scapineli; Beatriz Assis-Brazil; Rodolfo Vieira Maximiano; Tauanne Dias Amarante; Miriam Celi de Souza Nunes; Gerald Weber; Ana Luiza Maia
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.